Present and future of immune checkpoint blockade: Monotherapy to adjuvant approaches

Table 2 Clinical study outcomes of anti-programmed death-1 or anti-programmed death ligand-1 antibody in solid tumors

Ref.	Phase	Cancer type	No. of patients	Antibody type	Outcome
Hamid et al[75]	2	Melanoma	135	Lambrolizumab	RECIST: 1.1; RR: 38% (95%CI: 25-44)
Weber et al[85]	1	Melanoma	90	Nivolumab	RECIST: 1.1; RR: 25%
Brahmer et al[86]	1	Advanced cancers	207	Anti-PD-L1	OR: 6%-17%
Topalian et al[83]	1	Advanced cancers	296	Nivolumab	OR: 18%-36%

Dose indicates dose of anti-PD-1 antibody. RECIST: Response evaluation criteria in solid tumors; OR: Objective response, as defined by partial or complete tumor regression; RR: Response rate; PD-L1: Programmed death ligand-1.